Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 22,324

Document Document Title
WO/2018/068120A1
The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: a compound; the use of said compound; a synthetic intermediate in the preparation of comp...  
WO/2018/071058A1
Embodiments of the disclosure concern methods and compositions for delivering therapeutic, diagnostic or interventional moieties, such as complex and simple entities such as biologies, including at least cells, for example. The methods e...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/060213A1
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...  
WO/2018/060438A1
Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for ...  
WO/2018/064238A1
The addition of a salt to an ALA formulation reduces the degree of burning or irritation from ALA exposure during administration. This is particularly useful for an oral dissolve form of administration due to the extended time of ALA exp...  
WO/2018/060212A1
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...  
WO/2018/060704A1
Compounds of Formula (I), which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduct...  
WO/2018/060311A1
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preve...  
WO/2018/055539A1
The invention relates to an aqueous pharmaceutical composition comprising: (a) from about 1 IU/ml to about 500 IU/ml of buffered insulin glargine, and (b) one or more pharmaceutically acceptable excipients, wherein the pharmaceutical com...  
WO/2018/053036A1
The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlip...  
WO/2018/046719A1
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes...  
WO/2018/047894A1
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...  
WO/2018/044468A1
Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1α,25- dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidi...  
WO/2018/038803A1
The invention is related to fusion proteins of human somatostatin (e.g., SST-14 or SST-28) and human serum albumin, comprising a region at least 85% homologous to human somatostatin and a region at least 85% homologous to human serum alb...  
WO/2018/032787A1
A highly glycosylated human growth hormone fusion protein, comprising, from the N-terminus to the C-terminus, of a human growth hormone (hGH), a flexible peptide linker (L), and a human chorionic gonadotropin β-subunit carboxy-terminal ...  
WO/2018/028433A1
Provided is a use of Cellular Repressor of EIA-stimulated Genes CREG protein, in particular, provided is a use of the CREG protein or an active fragment thereof in the preparation of medicines for prevention and/or treatment of overweigh...  
WO/2018/028666A1
The present application relates a crystal of a compound represented by formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by formula (I), the salt thereof, and t...  
WO/2018/024224A1
A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the ...  
WO/2018/026748A1
The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyp...  
WO/2018/023003A1
Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.  
WO/2018/018097A1
The present invention relates to methods of treating mast cell tumors and soft tissue sarcomas using 6,7-epoxy-4,5,9, 12, 13,20-hexahydroxy-l-tigliaen-3-one derivatives in combination with at least one other pharmaceutically active agent...  
WO/2018/015497A3
The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The comp...  
WO/2018/015497A2
The invention provides compositions and methods for the use of oxytocin antagonists, such as substituted pyrrolidin-3-one oxime derivatives, among other compounds, in the treatment of subjects undergoing embryo transfer therapy. The comp...  
WO/2018/010656A1
A pyrrolidine derivative serving as a PPAR agonist, and applications thereof in treating diseases of pathways related to a PPAR receptor, such as nonalcoholic steatohepatitis, complication fibrosis, insulin resistance, primary biliary ch...  
WO/2018/012578A1
The present invention addresses the problem of providing a novel, safe, and side-effect-free ghrelin secretion promotor capable of enhancing the ghrelin secretory function present in the human body, wherein the promotor is provided in th...  
WO/2018/011015A1
The present invention relates to a low-dosed oral dosage form for treatment and/or prophylaxis of diseases, especially of endometriosis, polycystic ovary syndrome and/or atopic dermatitis. More particularly, the present invention concern...  
WO/2018/006688A1
Provided in the present invention is a use of a fulvestrant in the preparation of drugs for treating the growth hormone adenoma. By means of the technical solution, the present invention can effectively improve the prognosis of patients ...  
WO/2018/001232A1
The present invention relates to an acrylic acid-based derivative as represented by a general formula (I), stereoisomers and tautomers thereof, or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutica...  
WO/2018/003997A1
The present invention addresses the problem of providing a safe and easy-to-prepare cell preparation for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell preparation for prevention and/or treatment...  
WO/2018/005193A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2017/223457A1
A population of Brown adipose tissue (BAT) cells generated from embryonic stem cells (ES) or induced pluripotent stem cells (iPS), called iBAT, the use thereof, methods to obtain iBAT by directed differentiation of ES/iPS, and media comp...  
WO/2017/215602A1
Provided in the present invention is a use of doxycycline in the preparation of a medicine for treating or preventing aging diseases, wherein the doxycycline is administered at a dose of less than 2 μg/ml, and the aging diseases mainly ...  
WO/2017/211330A1
15β-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, ...  
WO/2017/211293A1
The present invention relates to a crystalline form of a succinate used as a dipeptidyl peptidase-4 inhibitor, and a manufacturing method, pharmaceutical composition, and application thereof. The invention specifically relates to a dipep...  
WO/2017/213268A1
The purpose of the invention is to provide an insulin secretion promoter having an action that effectively promotes insulin secretion, an insulin sensitizer having an action that effectively improves insulin resistance, an agent for prev...  
WO/2017/208076A1
Provided herein is an optimized method of enhancing endogenous gonadotropins and testosterone/estrogen production and concentrations comprising administration of a therapeutically effective amount of at least one GnRH agonist to a patien...  
WO/2017/208847A1
A pharmaceutical composition including 4.5-10.0 mass% of fulvestrant relative to the total mass of the pharmaceutical composition, 8-23 mass% of at least one polyhydric alcohol selected from propylene glycol and 1,3-butylene glycol relat...  
WO/2017/206827A1
Disclosed are a crystal form of an L-proline cocrystal of a sodium-glucose cotransporter 2 inhibitor, a preparation method therefor, and a pharmaceutical composition and a use therof. Particularly involved are the crystal form of the L-p...  
WO/2017/204277A1
The present invention provides an anti-TGF-beta3 antibody and a method of using the antibody. The anti-TGF-beta3 antibody according to the present invention has a binding activity to TGF-beta3 but does not have a neutralizing activity to...  
WO/2017/197904A2
A plurality of new crystal forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII and XIV of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin- 2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, as well as a preparation method and med...  
WO/2017/197904A3
A plurality of new crystal forms I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII and XIV of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin- 2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, as well as a preparation method and med...  
WO/2017/193824A1
An artemisinin analog as represented by formula (A) and application thereof in preparing a pharmaceutical product for promoting lipid catabolism and/or prevention or treatment of metabolism-related disease. The artemisinin analog promote...  
WO/2017/194030A1
A use for the protein function inhibitor DAPT in preparing medicine for treating endocrine diseases is provided in the present invention. By means of the technical solution, the present invention allows for effective amelioration of endo...  
WO/2017/195901A1
Disclosed are a screening method for drugs for the treatment of obesity-related diseases using as the indicator the ability of a candidate drug to inhibit the action of pentraxin 4 and a pharmaceutical composition for treating obesity-re...  
WO/2017/186793A1
The invention relates to chemical compounds that are useful in the treatment of a subject afflicted by a thyroid disease, in particular to compounds that exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and the...  
WO/2017/187375A1
A composition for the treatment of polycystic ovary syndrome, as well as the endocrine-gynecological and metabolic disorders associated therewith are described. In particular, the composition of the invention comprises inositol and extra...  
WO/2017/181277A1
Described herein are bioactive peptides that are modified at one or more positions with a PEG moiety. An example of such a PEGylated bioactive peptide is a GHRH analog that is modified at one or more positions with a PEG moiety. Also des...  
WO/2017/184811A1
A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or...  
WO/2017/179744A1
The present invention relates to: a pharmaceutical composition for preventing and treating diseases caused by the excessive release of steroid hormones, containing a pyruvate dehydrogenase kinase 4 (PDK4) activity inhibitor as an active ...  

Matches 1 - 50 out of 22,324